Published December 1, 2019 | Version v1
Journal article Open

Prognostic Efficacy Assessment of ACT Therapy and Quinine in Severe Falciparum Malaria

Authors/Creators

  • 1. Department of General Medicine, Ganesh Shankar Vidyarthi Memorial Medical College (GSVM Medical College), Kanpur
  • 2. Department of General Pediatrics, King George Medical University, Lucknow

Description

In this study, the changes in prognostic indicators such as haemoglobin levels, serum lactate levels, liver function
tests, blood sugar levels and glassgow coma scale in patients of severe falciparum malaria treated with Artesunate
combination therapy and Quinine have been observed. One hundred patients of severe falciparum malaria were selected
from medicine indoor wards. The patients were randomly assigned to artesunate based combination therapy or quinine
based therapy. Prognostic parameters like haemoglobin, glasgow coma scale, serum lactates, liver function test and blood
sugar levels were monitored. The present study suggests that artesunate is an effective alternative to quinine in the treatment
of severe malaria.The mortality, incidence of posttreatment hypoglycemia, coma recovery time, time to normalization of
plasma lactate levels and liver function tests, variability in Haemoglobin were not found to be statistically significant.
Occurrence of hypoglycemia and hearing disturbances in quinine treatment group was found to be statistically significant.

Files

4.pdf

Files (106.2 kB)

Name Size Download all
md5:e4b1c229a34e4ff530989d459184d497
106.2 kB Preview Download

Additional details

References

  • 1. Joseph V, Varma M, Vidhyasagar S, Mathew A. Comparison of the Clinical Profile and Complica- tions of Mixed Malarial Infections of Plasmodium Falciparum and Plasmodium Vivax versus Plasmodium Falciparum Mono-infection. 2011; 11 (3):377-82.
  • 2. Hanson J, Lee SJ, Mohanty S, Faiz MA, Anstey NM, Charunwatthana PK, et al. A Simple Score to Predict the Outcome of Severe Malaria in Adults. Clin Infect Dis. 2010;50(5):679-685.
  • 3. Evans JA, May J, Ansong D, Antwi S, Asafo-Adjei E, Nguah SB, Osei-Kwakye K, Akoto AO, Ofori AO, Sambian D, Sylverken J, Busch W, Timmann C, Agbenyega T, Horstmann RD. Capillary refill time as an independent prognostic indicator in severe and complicated malaria. J Pediatr. 2006;149(5):676- 81.
  • 4. Newton PN, Angus BJ, Chierakul W, Dondorp A, Ruangveerayuth R, Silamut K, Teerapong P, Suputtamongkol Y, Looareesuwan S,White NJ. Randomized comparison of artesunate and quinine in the treatment of severe falciparum malaria. Clin Infect Dis. 2003;37(1):7-16.
  • 5. H ar o o n N , A mich an d w ala K , S o lu M G . Comparative Efficacy of Quinine and Artesunate in the Treatment of Severe Malaria: A Randomized Controlled Trial. J & K Science. 2005; 7(1):1-4.
  • 6. Krishna S, Waller DW, ter Kuile F, Kwiatkowski D, Crawley J, Craddock CF, et al. Lactic acidosis and hypoglycaemia in children with severe malaria: pathophysiologicaland prognostic significance. Trans R Soc Trop Med Hyg. 1994;88(1):67-73.
  • 7. Mishra SK, Panigrahi P, Mishra R, Mohanty S. Prediction of outcome in adults with severe falciparum malaria: a new scoring system. Malaria Jour. 2007;6:24.
  • 8. Medana IM, Day NP, Sachanonta N, Mai NT, Dondorp AM, Pongponratn E, Hien TT, White NJ, Turner GD. Coma in fatal adult human malaria is not caused by cerebral oedema. Malar J. 2011;17;10 :267.
  • 9. Newton CR, Chokwe T, Schellenberg JA, Winstanley PA, Forster D, Peshu N, Kirkham FJ, Marsh K. Coma scales for children with severe falciparum malaria. 1997;91(2):161-5.
  • 10. Anil AC, Pankaj P. Jaundice in malaria. J Gastroenterol Hepatolo. 2005;20(9):1322–1332.
  • 11. White NJ, Warrell DA, Chanthavanich P, Looareesuwan S, Warrell MJ, Path MRC, et al. Severe Hypoglycemia and Hyperinsulinemia in Falciparum Malaria. N Engl J Med. 1983; 309:61- 66.
  • 12. Nicholas PJ, Nguyen H, Nguyen TH, Chau TTH, Phu LP, Can CL, et al. The pathophysiologic and prognostic significance of acidosis in severe adult malaria. 2000;28(6):1833-1840.
  • 13. Nosten F, Brasseur P. Combination Therapy for Malaria: The Way Forward? Drugs. 2002;62(9): 1315-1329
  • 14. Ogetii GN,Akech S, Jemutai J, Boga M, Kivaya E, Fegan G, Maitland K. Hypoglycaemia in severe malaria, clinical associations and relationship to quinine dosage. BMC Infect Dis. 2010 ;22;10:334.
  • 15. Perkins DJ, Were T, Davenport GC, Kempaiah P, Hittner JB, Ong'echa JM. Severe malarial anemia: innate immunity and pathogenesis. Int J Biol Sci. 2011;7(9):1427-42.
  • 16. Qigui Li and Peter Weina. Artesunate: The Best Drug in the Treatment of Severe and Complicated Malaria. Pharmaceuticals. 2010;3:2322-2332.
  • 17. Robinson T, Mosha F, Grainge M, Madeley R. Indicators of mortality in African adults with malaria. Trans R Soc Trop Med Hyg. 2006; 100(8) :719-24.
  • 18. Rolling T, Wichmann D, Schmiedel S, Burchard GD, Kluge S, Cramer JP. Artesunate versus quinine in the treatment of severe imported malaria : comparative analysis ofadverse events focussing on delayed haemolysis. Malar J. 2013;12:241.
  • 19. Yeung S, Pongtavornpinyo W, Hastings IM, Mills AJ, White HJ. Antimalarial drug resistance, artemisinin-based combination therapy, and the contribution of modeling to elucidating policy choices : Am J Trop Med Hyg . 2004;71(2): 179- 186
  • 20. Taylor TE, Molyneux ME, Wirima JJ, Fletcher A, Path, Morris K. Blood Glucose Levels in Malawian Children before and during the Administration of Intravenous Quinine for Severe falciparum Malaria. N Engl J Med. 1988; 319:1040-1047.
  • 21. Treeprasertsuk S, Silachamroon U, Krudsood S, Huntrup A, Suwannakudt P, Vannaphan S, et al. Ursodeoxycholic acid and artesunate in the treatment of severe falciparum malaria patients with jaundice. J Gastroenterol Hepatol. 2010;25(2):362- 8.
  • 22. von Seidlein L, Olaosebikan R, Hendriksen IC, Lee SJ, Adedoyin OT, Agbenyega T, et al. Predicting the clinical outcome of severe falciparum malaria in african children. Clin Infect Dis. 2012;54(8):1080- 90.